Application of clinical and molecular profiling data to improve patient outcomes in psoriatic arthritis

• Published in: Therapeutic Advances in Musculoskeletal Disease Vol. 15; p. 1759720X231192315
• Main Authors: FitzGerald, Oliver, Behrens, Frank, Barton, Anne, Bertheussen, Heidi, Boutouyrie-Dumont, Bruno, Coates, Laura, Davies, Owen, de Wit, Maarten, Fagni, Filippo, Goodyear, Carl S., Gurke, Robert, Hahnefeld, Lisa, Huppertz, Christine, Ioannidis, Vassilios, Ibberson, Mark, Katz, Arnon, Klippstein, Maximilian, Koehm, Michaela, Korish, Shimon, Mackay, Sina, Martin, David A., O’Sullivan, Denis, Patel, Khadijah, Rueping, Stefan, Schett, Georg, Scholich, Klaus, Schwenk, Jochen M., Siebert, Stefan, Simon, David, Vivekanantham, Arani, Pennington, Stephen R.
• Format: Book Review Journal Article
• Language: English
• Published: London, England SAGE Publications 01-01-2023; SAGE PUBLICATIONS, INC; SAGE Publishing
• Subjects: diagnosis; HIPPOCRATES; IMI; Medical diagnosis; Medicin och hälsovetenskap; Molecular biology; multi-omics; Pathogenesis; patient outcomes; psoriasis; Psoriatic arthritis; Review; IMI; psoriasis; multi-omics; diagnosis; HIPPOCRATES; patient outcomes; psoriatic arthritis
• ISSN: 1759-720X; 1759-7218; 1759-7218
• DOI: 10.1177/1759720X231192315

Achieving a good outcome for a person with Psoriatic Arthritis (PsA) is made difficult by late diagnosis, heterogenous clinical disease expression and in many cases, failure to adequately suppress inflammatory disease features. Single-centre studies have certainly contributed to our understanding of disease pathogenesis, but to adequately address the major areas of unmet need, multi-partner, collaborative research programmes are now required. HIPPOCRATES is a 5-year, Innovative Medicines Initiative (IMI) programme which includes 17 European academic centres experienced in PsA research, 5 pharmaceutical industry partners, 3 small-/medium-sized industry partners and 2 patient-representative organizations. In this review, the ambitious programme of work to be undertaken by HIPPOCRATES is outlined and common approaches and challenges are identified. It is expected that, when completed, the results will ultimately allow for changes in the approaches to diagnosing, managing and treating PsA allowing for better short-term and long-term outcomes.
Plain language summary
Improving outcomes in Psoriatic Arthritis
Psoriatic Arthritis (PsA) is a form of arthritis which is found in approximately 30% of people who have the skin condition, Psoriasis. Frequently debilitating and progressive, achieving a good outcome for a person with PsA is made difficult by late diagnosis, disease clinical features and in many cases, failure to adequately control features of inflammation. Research studies from individual centres have certainly contributed to our understanding of why people develop PsA but to adequately address the major areas of unmet need, multi-centre, collaborative research programmes are now required. HIPPOCRATES is a 5-year, Innovative Medicines Initiative (IMI) programme which includes 17 European academic centres experienced in PsA research, 5 pharmaceutical industry partners, 3 small-/medium-sized industry partners and 2 patient representative organisations (see appendix). In this review, the ambitious programme of work to be undertaken by HIPPOCRATES is outlined and common approaches and challenges are identified. The participation of patient research partners in all stages of the work of HIPPOCRATES is highlighted. It is expected that, when completed, the results will ultimately allow for changes in the approaches to diagnosing, managing and treating PsA allowing for improvements in short-term and long-term outcomes.